Inhibition of plasmin protects against colitis in mice by suppressing matrix metalloproteinase 9-mediated cytokine release from myeloid cells

Gastroenterology

Volumn 148, Issue 3, 2015, Pages 565-578.e4

  Munakata, Shinya ^a,b   Tashiro, Yoshihiko ^a,b   Nishida, Chiemi ^a,b   Sato, Aki ^a   Komiyama, Hiromitsu ^a,b   Shimazu, Hiroshi ^a   Dhahri, Douaa ^a   Salama, Yousef ^a   Eiamboonsert, Salita ^a   Takeda, Kazuyoshi ^b   Yagita, Hideo ^b   Tsuda, Yuko ^c   Okada, Yoshio ^c   Nakauchi, Hiromitsu ^a   Sakamoto, Kazuhiro ^b   Heissig, Beate ^a,b   Hattori, Koichi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

IBD; Mouse Model; Plasminogen; UC

Indexed keywords

CD11B ANTIGEN; CD40 ANTIGEN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GELATINASE B; PLASMIN; TUMOR NECROSIS FACTOR; CXCL5 PROTEIN, MOUSE; DEXTRAN SULFATE; DIPEPTIDE; IL1B PROTEIN, MOUSE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MMP9 PROTEIN, MOUSE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; YO 2 COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; IMMUNOHISTOCHEMISTRY; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DISEASE MODEL; IMMUNOLOGY; INFLAMMATION; INTESTINE MUCOSA; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; NEUTROPHIL; SECRETION (PROCESS);

ANIMALS; ANTIGENS, CD40; CHEMOKINE CXCL5; COLITIS; DEXTRAN SULFATE; DIPEPTIDES; DISEASE MODELS, ANIMAL; FIBRINOLYSIN; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTESTINAL MUCOSA; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; MYELOID CELLS; NEUTROPHILS; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923884605     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.12.001     Document Type: Article

References (41)

1. D.K. Podolsky Inflammatory bowel disease N Engl J Med 347 2002 417 429
2. B. Heissig, C. Nishida, and Y. Tashiro Role of neutrophil-derived matrix metalloproteinase-9 in tissue regeneration Histol Histopathol 25 2010 765 770
3. F.E. Castaneda, B. Walia, and M. Vijay-Kumar Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP Gastroenterology 129 2005 1991 2008
4. J.W. Mao, X.M. He, and H.Y. Tang Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats World J Gastroenterol 18 2012 7063 7069
5. H.R. Lijnen, J. Silence, and G. Lemmens Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system Thromb Haemost 79 1998 1171 1176
6. B. Heissig, M. Ohki-Koizumi, and Y. Tashiro New functions of the fibrinolytic system in bone marrow cell-derived angiogenesis Int J Hematol 95 2012 131 137
7. M. Ohki, Y. Ohki, and M. Ishihara Tissue type plasminogen activator regulates myeloid-cell dependent neoangiogenesis during tissue regeneration Blood 115 2010 4302 4312
8. Y. Tashiro, C. Nishida, and K. Sato-Kusubata Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice Blood 119 2012 6382 6393
9. B. Heissig, L.R. Lund, and H. Akiyama The plasminogen fibrinolytic pathway is required for hematopoietic regeneration Cell Stem Cell 1 2007 658 670
10. R.A. Black, C.T. Rauch, and C.J. Kozlosky A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 1997 729 733
11. K. Hattori, T. Hirano, and C. Ushiyama A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice Blood 90 1997 542 548
12. M.F. Neurath, I. Fuss, and M. Pasparakis Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice Eur J Immunol 27 1997 1743 1750
13. W.F. Doe, and B. Dorsman Chronic inflammatory bowel disease-increased plasminogen activator secretion by mononuclear phagocytes Clin Exp Immunol 48 1982 256 260
14. J.C. Souto, E. Martinez, and M. Roca Low levels of plasminogen activator inhibitor type 1 in patients with inflammatory bowel disease Fibrinolysis 8 1994 359 363
15. H.H. Uhlig, B.S. McKenzie, and S. Hue Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology Immunity 25 2006 309 318
16. C. Cayatte, B. Joyce-Shaikh, and F. Vega Biomarkers of therapeutic response in the IL-23 pathway in inflammatory bowel disease Clin Transl Gastroenterol 3 2012 e10
17. Y. Okada, Y. Tsuda, and M. Tada Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship Chem Pharm Bull (Tokyo) 48 2000 1964 1972
18. J.T. Peterson Matrix metalloproteinase inhibitor development and the remodeling of drug discovery Heart Fail Rev 9 2004 63 79
19. H.S. Cooper, S.N. Murthy, and R.S. Shah Clinicopathologic study of dextran sulfate sodium experimental murine colitis Lab Invest 69 1993 238 249
20. S. Wirtz, C. Neufert, and B. Weigmann Chemically induced mouse models of intestinal inflammation Nat Protocols 2 2007 541 546
21. B. Heissig, K. Hattori, and S. Dias Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand Cell 109 2002 625 637
22. E. Lee, R. Enomoto, and K. Takemura A selective plasmin inhibitor, trans-aminomethylcyclohexanecarbonyl-L-(O-picolyl)tyrosine-octylamide (YO-2), induces thymocyte apoptosis Biochem Pharmacol 63 2002 1315 1323
23. A.A. van Bodegraven, M. Schoorl, and R.K. Linskens Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis Eur J Gastroenterol Hepatol 14 2002 413 418
24. J.D. Vassalli, J.M. Dayer, and A. Wohlwend Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages J Exp Med 159 1984 1653 1668
25. Y. Naito, T. Takagi, and M. Kuroda An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice Inflamm Res 53 2004 462 468
26. J.F. Fisher, and S. Mobashery Recent advances in MMP inhibitor design Cancer Metastasis Rev 25 2006 115 136
27. J. Song, C. Wu, and X. Zhang In vivo processing of CXCL5 (LIX) by matrix metalloproteinase (MMP)-2 and MMP-9 promotes early neutrophil recruitment in IL-1beta-induced peritonitis J Immunol 190 2013 401 410
28. T. Zou, C. Ling, and Y. Xiao Exogenous tissue plasminogen activator enhances peripheral nerve regeneration and functional recovery after injury in mice J Neuropathol Exp Neurol 65 2006 78 86
29. A.A. Vrij, J. Rijken, and J.W. van Wersch Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis Pathophysiol Haemost Thromb 33 2003 75 83
30. I.E. Koutroubakis Therapy insight: vascular complications in patients with inflammatory bowel disease Nat Clin Pract Gastroenterol Hepatol 2 2005 266 272
31. K. Kume, M. Yamasaki, and M. Tashiro Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis Intern Med 46 2007 1323 1329
32. R.H. Salter, and A.E. Read Epsilon-aminocaproic acid therapy in ulcerative colitis Gut 11 1970 585 587
33. D. Hollanders, J.M. Thomson, and P.F. Schofield Tranexamic acid therapy in ulcerative colitis Postgrad Med J 58 1982 87 91
34. A. Sato, C. Nishida, and K. Sato-Kusubata Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking Leukemia 29 2015 145 156
35. K.L. Kolho, T. Sipponen, and E. Valtonen Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease Int J Colorectal Dis 29 2014 43 50
36. M.J. Mohan, T. Seaton, and J. Mitchell The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity Biochemistry 41 2002 9462 9469
37. G. Jarnerot, E. Hertervig, and I. Friis-Liby Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study Gastroenterology 128 2005 1805 1811
38. P. Rutgeerts, G. Van Assche, and S. Vermeire Optimizing anti-TNF treatment in inflammatory bowel disease Gastroenterology 126 2004 1593 1610
39. M. Sans, J. Panes, and E. Ardite VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis Gastroenterology 116 1999 874 883
40. H. Rosen, and S. Gordon Monoclonal antibody to the murine type 3 complement receptor inhibits adhesion of myelomonocytic cells in vitro and inflammatory cell recruitment in vivo J Exp Med 166 1987 1685 1701
41. J. Mei, Y. Liu, and N. Dai Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice J Clin Invest 122 2012 974 986